Antiphospholipid syndrome during allergic bronchopulmonary aspergillosis.
Niitsuma
T
T
Third Department of Internal Medicine, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. t-niitsu@tokyo-med.ac.jp
Nukaga
M
M
Izawa
A
A
Tsuyuguchi
M
M
Tsuboi
N
N
Hayashi
T
T
D016736:Antiphospholipid Syndrome / Q000188:drug therapy / Q000209:etiology*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000150:complications*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D005938:Glucocorticoids; D006493:Heparin; D011239:Prednisolone; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator